Last reviewed · How we verify
Vonoprazan, Amoxicillin and Clarithromycin
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori infection eradication (first-line or rescue therapy).
At a glance
| Generic name | Vonoprazan, Amoxicillin and Clarithromycin |
|---|---|
| Sponsor | Kaohsiung Medical University |
| Drug class | Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H+/K+-ATPase pump to reduce gastric acid secretion, creating an environment where amoxicillin and clarithromycin can effectively penetrate and eliminate H. pylori. The combination leverages vonoprazan's superior acid suppression compared to proton pump inhibitors, which enhances antibiotic efficacy and bacterial eradication rates. This regimen is designed as a first-line or rescue therapy for H. pylori infection.
Approved indications
- Helicobacter pylori infection eradication (first-line or rescue therapy)
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial (PHASE4)
- Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: